Orforglipron

Description

Orforglipron is an oral small molecule (non-peptide) glucagon-like peptide-1 receptor agonist (GLP-1RA). Orforglipron is highly selective and has the characteristic of favoring G protein signal activation, while avoiding the degradation problem of peptide-based drugs. It can not only maintain the efficacy of GLP-1 but also improve tolerance and patient acceptance, which does not require restrictions on diet and water intake.

Clinical Research Application

Type 2 diabetics

GLP-1 receptor agonists are glucose-dependent and enhance insulin secretion, playing a crucial role in the management of type 2 diabetes. Orforglipron, as an innovative GLP-1RA, demonstrated satisfactory safety and efficacy in the early treatment of type 2 diabetic patients in clinical trials.

Obesity

Orforglipron activates the GLP-1 receptor, effectively suppressing appetite, reducing food intake, and simultaneously slowing down gastric emptying and increasing satiety. The results of the phase Ⅱ clinical studies on Orforglipron showed that obese or overweight adults who received high-dose Orforglipron treatment lost an average of 14.7% of their body weight after 36 weeks.

Other potential applications

Orforglipron can reduce fat deposition in the upper airway and improve the control of the muscles surrounding the respiratory tract, thereby alleviating or eliminating symptoms of sleep apnea.

The phase Ⅲ clinical trial of Orforglipron for the treatment of obesity, type 2 diabetes and obstructive sleep apnea (OSA) is currently underway.